Bayer Corporation

Grifols Worldwide Operations Limited

Grifols Therapeutics Inc.

Grifols, S.a.

Talecris Biotherapeutics, Inc.

Glaxo Wellcome Inc.

Thomas P Zimmerman

Charles Miller

Valery Novokhatny

James Rebbeor

Jennifer Audrey Hunt

Eric Allgaier

Anthony Klos

Kevin Wee

Michelle StPeter

Kelly Glancy

Gary J Jesmok

Shan Jiang

George A Baumbach

Edward Koepf

Christopher A Dadd

David Ownby

Kyle A Landskroner

Senthil Ranganathan

Tonny Dessources

Kathryn K Taylor

Rebecca Silverstein

Anthony Caronna

Kenya Stokes

James Colandene

Luis Molina

James D Colandene

Myles Lindsay

Tony Dessources

Valery B Novokhatny

Compositions include highly concentrated Alpha-1 Proteinase Inhibitor (A1PI) in a concentration greater than or equal to 100 mg/ml. Pharmaceutical compositions can be prepared from these compositions. The pharmaceutical compositions can be suitable for subcutaneous administration. The highly concentrated A1PI solutions can be obtained by single-pass tangential flow filtration (SPTFF).

Composition comprising highly-concentrated Alpha1 proteinase inhibitor and method for obtaining thereof

Compositions include highly-concentrated Alpha-1 Proteinase Inhibitor (A1PI) in a concentration greater than or equal to 100 mg/ml. Pharmaceutical compositions can be prepared from these compositions. The pharmaceutical compositions can be suitable for subcutaneous administration. The highly-concentrated A1PI solutions can be obtained by single-pass tangential flow filtration (SPTFF).

Composition comprising highly-concentrated &#x3b1;1 proteinase inhibitor and method for obtaining thereof

Composition comprising highly-concentrated ALPHA1 proteinase inhibitor and method for obtaining thereof

Described herein are methods for purifying recombinant, cell culture derived alpha-protease inhibitor and removing a colored species that co-purifies with the recA1PI protein. Also described are methods for reducing the iron in cell culture derived alpha-protease inhibitor.

Purification of cell culture derived alpha1 protease inhibitor

The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent.

Reversibly inactivated acidified plasmin composition

[object Object]

Compositions and methods for preparing plasminogen, in particular recombinant plasminogen, and compositions and methods of utilizing same for preparing plasmin are provided.

Compositions, methods and kits for preparing plasminogen and plasmin prepared therefrom

A streptokinase immobilized on a surface, in particular an immobilized plasmin-resistant streptokinase, and compositions, methods and kits of utilizing same for preparing plasmin are provided.

Composition, method, and kit for preparing plasmin

A method of treating a subject, the method including administring a composition that includes a reversibly inactivated acidfied plasmin substantially free of a plasminogen activator, in a low buffering capacity buffer, wherein the composition is a solution suitable for pharmacenutical use that can be raised to physiological pH by adding no more than about 5 volumes of serum to the solution relative to a volume of the solution.

Reversibly inactivated acidified plasmin

Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus.

Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin

The invention provides an improved method of thrombolytic therapy by the direct admiistration of active plasmin to a clot site via catheter. An active, stable preparation of plasmin is provided, as is a process for activation and isolation of active plasmin.

Method of thrombolysis by local delivery of active plasmin

A method and device for activating and applying a solution of fibrinogen to form fibrin glue at a desired site. The method includes contacting the solution of fibrinogen with immobilized thrombin under conditions that result in a solution of polymerizable fibrin and delivering the activated solution to the desired site. The device includes a housing having a compartment for a solution of fibrinogen, a container for immobilized thrombin, a structure following the solution of fibrinogen to be brought into contact with the immobilized thrombin under conditions which permit the activation of the fibrinogen to polymerizable fibrin, and a structure allowing for delivery of the activated solution to the desired site.

Method and device for delivering fibrin glue

Nitric oxide synthase inhibitors for inhibiting the production of airway

A method and device for activating and applying a solution of fibrinogen to a desired site. The method includes contacting the solution of fibrinogen with immobilized thrombin resulting in an activated solution of polymerizable fibrin, and delivering the activated solution to the desired site. The device includes a housing having a compartment for a solution of fibrinogen, immobilized thrombin, a structure for bringing the solution of fibrinogen in contact with the immobilized thrombin under conditions which permit the activation of the fibrinogen resulting in polymerizable fibrin, and a structure for delivery of the activated solution to the desired site.

Growing community of inventors

Raleigh, NC, United States of America

Thomas P Zimmerman